GSK plc
NYSE:GSKDrug Manufacturers - General
-$1.34 today
- Market cap
- $97.53B
- Beta
- 0.29
- P/E (TTM)
- 13.3
- EPS (TTM)
- $1.45
- Dividend yield
- 3.48%
Volume 2.02M
Average 4.07M
GSK Net Income
Bottom-line profit, the starting point for calculating cash from operations.
GSK plcNYSE: GSK
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income dips below year-ago levels
Q2 FY2026 net income of £437.26M fell 73.4% year over year, behind the +41.0% change in trailing-twelve-month net income. Sequentially, it fell 76.2% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Net income amounted to 17.1% of revenue in FY2025, up 7.7 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 16 analysts of £7.5B (+34.1%) for the fiscal year ending Dec 2026, a slowdown from the +89.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- £437.26M-76.2% QoQ
- Last fiscal yearDec 2025
- £5.59B+89.5% YoY
- LTMJun 2026
- £5.62B+41.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -73.4% | -24.2% | +49.2 pp |
| 1 year | +89.5% | +34.1% | -55.3 pp |
| 3-year CAGR | +0.6% | +14.2% | +13.6 pp |
| 5-year CAGR | +9.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
GBP · from the cash flow
- Latest · FY2025
- 5.59B GBP
- Year-over-year change
- +89.5%
- 4-year CAGR
- +12.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.59B | +89.5% |
| FY2024 | 2024-12-31 | 2.95B | -51.8% |
| FY2023 | 2023-12-31 | 6.13B | +11.5% |
| FY2022 | 2022-12-31 | 5.49B | +56.3% |
| FY2021 | 2021-12-31 | 3.52B | — |
Net Income vs competitors
How GSK compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +41.0% is the 2nd highest of 10, against a peer median of -6.4%.
- Net income amounts to 16.9% of revenue for GSK, versus a peer median of 19.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 116.44B DKK | +4.8% | +22.6% | 35.3% | |
| LTM Jun 2026 | $26.71B USD | +93.6% | +49.0% | 33.5% | |
| LTM Sep 2026 | $16.1B USD | -35.9% | +14.3% | 16.2% | |
| LTM Jun 2026 | $12.76B USD | -6.4% | +32.5% | 22.9% | |
| LTM Sep 2026 | $11.82B USD | +15.4% | +59.9% | 19.0% | |
| LTM Jun 2026 | $8.74B USD | +32.1% | +5.6% | 22.9% | |
| LTM Jun 2026 | £5.62B GBP | +41.0% | +0.6% | 16.9% | |
| LTM Jun 2026 | $4.37B USD | -59.4% | -37.2% | 6.9% | |
| LTM Jun 2026 | €3.96B EUR | -46.8% | -11.2% | 8.1% | |
| LTM Jun 2026 | $3.17B USD | -80.7% | +7.9% | 4.8% | |
| Peer median (excluding GSK) | — | -6.4% | +14.3% | 19.0% | |
Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 3.52B | 5.49B | 6.13B | 2.95B | 5.59B |
| Depreciation & Amortization | 2.12B | 2.15B | 2.29B | 2.55B | 2.31B |
| Deferred Income Tax | 0 | (965.72M) | (1.08B) | 0 | 0 |
| Stock-Based Compensation | 343M | 0 | 0 | 344M | 0 |
| Change in Working Capital | 1.39B | (1.67B) | (1.06B) | 2.09B | (608.37M) |
| Accounts Receivables | (1.16B) | (758.78M) | (806.74M) | 340M | 0 |
| Inventory | 51M | (331.35M) | (527.05M) | (294M) | 0 |
| Accounts Payables | 0 | 608.5M | (18.65M) | 0 | 0 |
| Other Working Capital | 2.5B | (1.19B) | 288.39M | 2.04B | (608.37M) |
| Other Non-Cash Items | 584M | 3.16B | 1.61B | (1.38B) | (153.41M) |
| Operating Cash Flow | 7.95B | 8.16B | 7.89B | 6.55B | 7.14B |
| Capital Expenditures | (2.65B) | (1.41B) | (1.63B) | (2.98B) | (1.32B) |
| Acquisitions (Net) | 185M | (3.79B) | (1.72B) | 1.37B | (4.37B) |
| Purchases of Investments | 0 | (177.38M) | (152.9M) | 0 | (89.98M) |
| Sales of Investments | 18M | 294.4M | 2.37B | 21M | 195.62M |
| Other Investing Activities | (1.03B) | (4.43B) | 14.92M | (1.22B) | 1.46B |
| Investing Cash Flow | (1.78B) | (10.88B) | (2.4B) | (1.23B) | (5.72B) |
| Debt Repayment | (2B) | (5.69B) | (2.95B) | (1.17B) | 1.47B |
| Common Stock Issued | 21M | 30.79M | 12.43M | 20M | 14.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (4B) | (4.27B) | (2.79B) | (2.44B) | (2.51B) |
| Other Financing Activities | (1.61B) | 11.98B | (341.84M) | (1.14B) | (573.16M) |
| Financing Cash Flow | (7.59B) | 2.05B | (6.07B) | (4.73B) | (1.59B) |
| Effect of Forex Changes | (29M) | (637.97M) | (153.84M) | (54M) | (32.94M) |
| Net Change in Cash | (1.44B) | (1.31B) | (735.58M) | 545M | (206.06M) |
| Free Cash Flow | 5.3B | 6.75B | 6.26B | 3.57B | 5.82B |
GSK plc
NYSE:GSK
Intrinsic Alpha fair value
Locked
Current Price
$48.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.